Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

lopment, compared to 79 people at the same date in 2007.

In the nine months ended September 30, 2008, administrative and selling expenses amounted to EUR8.4 million, compared to EUR8.8 million in the nine months ended September 30, 2007. During the first nine months of 2008, general and administrative expenses were EUR5.3 million compared to EUR5.6 million for the corresponding period of 2007 and represented mainly personnel expenses in administrative and financial functions, as well as the remuneration of corporate officers, including stock option, bonus share and warrant attributions. These expenses also included structural costs such as leases, property service charges and maintenance costs (excluding structural costs related to research and development activities), legal and accounting fees and other external administrative costs. For the first nine months of 2008, selling expenses totaled EUR3.1 million, compared to EUR3.2 million for the same period of 2007, and correspond to the market analysis activities for naproxcinod, as well as the business development and communication activities of the Company. The Company anticipates an increase in its selling expenses during the fourth quarter of 2008, due to activities linked to the commercial launch preparation for naproxcinod. On September 30, 2008, the Company employed 37 people in its selling, general, and administrative departments, compared to 32 people on September 30, 2007.

Other income

During the nine months ended September 30, 2008, other income totaled EUR3.3 million, compared to EUR3.2 million on September 30, 2007. Other income corresponds to the operational subsidies from the research tax credits which were previously deducted from research and development expenses until December 31, 2007.

Operating result

In the nine months ended September 30, 2008, the operating loss reached EUR54.2 million, compared to EUR17.4 million in the corresponding period of 2007. This situa
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... 2011 CryoLife, Inc. (NYSE: CRY ), an ... today that it has filed an IDE with ... clinical trials for the purpose of obtaining Pre-Market Approval (PMA) ... surgical procedures or following traumatic injuries. PerClot ...
... 2011 Orexigen ® Therapeutics, Inc. (Nasdaq: ... showed that overweight and obese patients treated with ... 24-hour circadian patterns over one year of treatment. ... monitoring (ABPM) sub-study of the COR-II trial that ...
... OMER ), a biopharmaceutical company committed to ... and disorders of the central nervous system, today announced ... officer, is scheduled to present at the 10th Annual ... this week.  The presentation is scheduled for Tuesday, April ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 2Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 3Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 4
(Date:7/10/2014)... 10, 2014Women in the West African nation Burkina ... planning option. Sayana Press has the potential to ... the health system and in communities by combining ... Depo-Provera (depot medroxyprogesterone acetate)with the BD Uniject injection ... four African countries expected to begin introducing Sayana ...
(Date:7/9/2014)... Caesarean section have a different intestinal flora than children delivered ... is the case and what it means for the immune ... therefore decided to scrutinise the impact of birth on the ... mouse pups. , The study shows that ... of cells that strengthen the immune system, says Camilla Hartmann ...
(Date:7/9/2014)... hunts in Indiana state parks have helped restore the ... by overabundant populations of white-tailed deer, a Purdue study ... associate professor of forest ecology, found that a 17-year-long ... in state parks has successfully spurred the regrowth of ... browsing deer. , Jenkins said that while hunting ...
Breaking Biology News(10 mins):Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3Mouse study: Natural birth may strengthen the immune system 2Hunting gives deer-damaged forests in state parks a shot at recovery 2
... in the Canadian Rockies are stifling the mating choices ... researchers. , Smaller and less abundant alpine meadows--largely the ... pool, creating a pattern that could lead to the ... Roland, a biological scientist at the University of Alberta ...
... and bitter tastes may reside in the same taste bud ... discovery of a chemical messenger called neuropeptide Y (NPY) in ... is active in the brain and gut, this is the ... taste bud cells. , That finding gives scientists a deeper ...
... which is involved in cellular immune signaling, scientists have succeeded ... This old protein with a new twist may eventually be ... Stat1 is involved in immune responses that are initiated by ... cells of the immune system in response to challenges by ...
Cached Biology News:Expanding forests darken the outlook for butterflies, study shows 2Bitter or sweet? The same taste bud can tell the difference 2Bitter or sweet? The same taste bud can tell the difference 3Engineered molecule amplifies body's immune response 2Engineered molecule amplifies body's immune response 3
...
... T4 DNA Ligase catalyzes the formation ... ATP between double-stranded DNAs with 3' hydroxyl ... DNA Ligase buffer optimizes ligation which can ... nucleic acids are not substrates for this ...
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Biology Products: